<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00780975</url>
  </required_header>
  <id_info>
    <org_study_id>APL-B-011-02</org_study_id>
    <nct_id>NCT00780975</nct_id>
  </id_info>
  <brief_title>A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer</brief_title>
  <official_title>A Phase II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Aplidin® as a 3-hour IV Infusion Every 2 Weeks, in Relapsing or Refractory Patients With Androgen-independent Prostate Adenocarcinoma..</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaMar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to test the safety and efficacy of an investigational chemotherapy agent in&#xD;
      patients with advanced prostate cancer. Subjects who meet all entry criteria and have signed&#xD;
      the informed consent will be enrolled in the study. Participants will be required to attend&#xD;
      regular clinic visits to receive study medication and have their status monitored. A detailed&#xD;
      explanation can be provided by the investigator conducting the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate cancer is the most common non-cutaneous cancer diagnosed in men in the United&#xD;
      States. The majority of deaths occur in men with androgen-independent prostate cancer [AIPC].&#xD;
      Although 80% of men with advanced cancer will initially respond to androgen ablation with&#xD;
      disease regression or stabilization, their malignancies become resistant to such therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor recruitment&#xD;
  </why_stopped>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Patients With a ≥ 50% Prostate-specific Antigen (PSA) Decline Post-therapy</measure>
    <time_frame>All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Tumor Response According to RECIST</measure>
    <time_frame>All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first</time_frame>
    <description>Patients with an objective tumor response (complete response [CR] or partial response [PR]) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST), See Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000; 92:205-16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first</time_frame>
    <description>To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after 2 previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy.&#xD;
PFS defined as time from the first day of study treatment to the day of a negative outcome (progression according to RECIST (Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000; 92:205-16) or death) or last contact. If any patient is lost to follow up before disease progression, the PFS will be censored at the date of the last tumor assessment. If there are no tumor assessments the patient will be censored at the first drug administration date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first</time_frame>
    <description>To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after two previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy.&#xD;
Survival is measured from the first day of study treatment to death or day of their last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Improvement Rate</measure>
    <time_frame>2-7 days for the pain stabilization required at baseline to ensure that baseline values are stable and reliable. The follow-up period was up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment</time_frame>
    <description>To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after two previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy.&#xD;
Expressed as a change in pain intensity according to the pain intensity score on the 100 mm VAS (Visual Analogue Scale) and/or change in analgesic (morphine-equivalent mg) requirements after a pain stabilization period of 2-7 days&#xD;
Visual Analogue Scale (VAS), expressed in the pain intensity score on the 100 mm VAS scale (0=least possible pain to 100=worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA Slope Between Baseline PSA Value and Nadir After the Start of Treatment</measure>
    <time_frame>From baseline until progression or initiation of another anticancer therapy, death or one year after the last treatment visit of the last patient, whichever occurred first.</time_frame>
    <description>To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after two previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy.&#xD;
It was calculated as (nadir value-baseline value)/(nadir date-baseline date). Modifications in the slope of PSA changes before and after the start of treatment with Aplidin will also be explored.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aplidin (Plitidepsin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aplidin (plitidepsin)</intervention_name>
    <description>Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent before starting any study-specific procedure. If any patient&#xD;
             is unable to give consent, it may be obtained from the patient's legal representative&#xD;
             if in accordance with local laws and regulations.&#xD;
&#xD;
          2. Men with castrate metastatic adenocarcinoma of the prostate, with the following&#xD;
             characteristics:&#xD;
&#xD;
               -  Confirmed pathological diagnosis.&#xD;
&#xD;
               -  Metastatic disease (radiologically documented).&#xD;
&#xD;
               -  All patients with chemical castration must have a serum testosterone level below&#xD;
                  50 ng/ml. There is no need to document a serum testosterone in patients having a&#xD;
                  prior surgical castration2.&#xD;
&#xD;
               -  Baseline PSA &gt; 5 ng/ml (according to the recommendations from the&#xD;
                  Prostate-Specific Antigen Working Group2).&#xD;
&#xD;
               -  Androgen-independent progressive disease, as defined by detectable, rising PSA in&#xD;
                  two consecutive measurements at least one week apart:&#xD;
&#xD;
                    -  If PSA responded to a prior therapy, progression occurs when the PSA is 50%&#xD;
                       above the nadir level.&#xD;
&#xD;
                    -  If PSA did not respond to a prior therapy, progression occurs when the PSA&#xD;
                       increases by 25% or more above pretreatment levels.&#xD;
&#xD;
                    -  In both cases, the increase in absolute value PSA level must be at least 5&#xD;
                       ng/ml, and must be confirmed by a second measurement a minimum of 1 week&#xD;
                       later.&#xD;
&#xD;
               -  Patients must have received prior docetaxel-based chemotherapy.&#xD;
&#xD;
          3. Recovery from any toxicity derived from previous treatments. The presence of alopecia&#xD;
             and NCI-CTC grade &lt; 2 sensitive peripheral neuropathy is allowed.&#xD;
&#xD;
          4. Age &gt; 18 years.&#xD;
&#xD;
          5. Performance status (ECOG) &lt; 2.&#xD;
&#xD;
          6. Life expectancy &gt; 3 months.&#xD;
&#xD;
          7. Adequate renal, hepatic, and bone marrow function (assessed &lt; 14 days before inclusion&#xD;
             in the study):&#xD;
&#xD;
               -  Neutrophil count ³ 1.5 x 109/L.&#xD;
&#xD;
               -  Platelet count ³ 100 x 109/L. Hemoglobin &gt; 9 g/dl.&#xD;
&#xD;
               -  Creatinine clearance ³ 40 ml/min (calculated from the Cockcroft and Gault&#xD;
                  formula), see Appendix 3.&#xD;
&#xD;
               -  Serum bilirubin * 1.5 mg/dl.&#xD;
&#xD;
               -  AST, ALT &lt; 2.5 x ULN (&lt; 5 x ULN in case of liver metastasis).&#xD;
&#xD;
               -  Albumin &gt; 25 g/L.&#xD;
&#xD;
          8. Left ventricular ejection fraction within normal limits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior therapy with Aplidin®.&#xD;
&#xD;
          2. Concomitant therapy with any anti-tumor agent, including glucocorticoids at a daily&#xD;
             dose greater than 10 mg prednisone or equivalent, except when they were indicated for&#xD;
             symptom control, provided that disease progression was documented while on steroids.&#xD;
&#xD;
          3. Small cell carcinoma of the prostate.&#xD;
&#xD;
          4. More than two previous lines of systemic therapy for patient's castrate metastatic&#xD;
             disease, considering biological agents or chemotherapy as systemic therapy.&#xD;
&#xD;
          5. Patients with progressive measurable disease but without increased PSA value&#xD;
             (according to the consensus recommendations) will not be considered eligible.&#xD;
&#xD;
          6. Wash-out periods less than:&#xD;
&#xD;
               -  6 weeks after the last dose of a nitroso-urea or high dose chemotherapy&#xD;
&#xD;
               -  4 weeks after the last dose of other chemotherapies or biological agents&#xD;
&#xD;
               -  6 weeks after the end of treatment with extensive external beam radiation (more&#xD;
                  than 25% of bone marrow distribution) or radionuclide therapy.&#xD;
&#xD;
               -  4 weeks after the end of treatment with palliative radiation involving less than&#xD;
                  25% of bone marrow reserves.&#xD;
&#xD;
               -  4 weeks for major prior surgery&#xD;
&#xD;
               -  30 days after receiving any other investigational product&#xD;
&#xD;
          7. Men of reproductive potential who are not using effective contraceptive methods,&#xD;
             considering complete abstinence from intercourse throughout the treatment with the&#xD;
             study drug and for at least 6 months after completion or premature discontinuation&#xD;
             from the study as an effective contraceptive method, to be sure that the patient's&#xD;
             female partner does not become pregnant.&#xD;
&#xD;
          8. History of another neoplastic disease. The exceptions are:&#xD;
&#xD;
             8.1 Non-melanoma skin cancer. 8.2 Any other cancer curatively treated with no evidence&#xD;
             of disease for at least 10 years.&#xD;
&#xD;
          9. Known symptomatic cerebral or leptomeningeal involvement.&#xD;
&#xD;
         10. Other relevant diseases or adverse clinical conditions:&#xD;
&#xD;
               -  History or presence of unstable angina, myocardial infarction, valvular heart&#xD;
                  disease or congestive heart failure.&#xD;
&#xD;
               -  Previous mediastinal radiotherapy.&#xD;
&#xD;
               -  Uncontrolled arterial hypertension despite optimal medical therapy.&#xD;
&#xD;
               -  Previous treatment with doxorubicin at cumulative doses in excess of 400 mg/m².&#xD;
&#xD;
               -  Symptomatic arrhythmia or any arrhythmia requiring treatment.&#xD;
&#xD;
               -  Abnormal ECG as detailed below:&#xD;
&#xD;
                    -  QT interval prolongation:&#xD;
&#xD;
                    -  QTc&gt; 480 msec.&#xD;
&#xD;
                    -  Left ventricular hypertrophy :&#xD;
&#xD;
                    -  Sokolow Index: (R V5 or V6) + S V1)&gt; 3.5mv.&#xD;
&#xD;
                    -  Left bundle-branch block:&#xD;
&#xD;
                    -  Complete: QRS&gt; 0.12 sec. No Q wave is seen in leads V5 and V6. A notched R&#xD;
                       wave is seen in left leads and a notched S wave in right side leads.&#xD;
&#xD;
                    -  Right bundle-branch block:&#xD;
&#xD;
                    -  Complete: QRS&gt; 0.12 sec. Secondary R (R') wave in leads V1-V2. Slurred S&#xD;
                       wave in leads D1 ,avL, V5 and V6.&#xD;
&#xD;
                    -  Second-degree atrioventricular (av) block:&#xD;
&#xD;
                    -  Mobitz I AV block, or Wenckebach block: Progressive prolongation of the PR&#xD;
                       interval causing progressive R-R interval shortening until a P wave fails to&#xD;
                       conduct the ventricle. The RR interval containing the blocked P wave is&#xD;
                       shorter than the sum of the twPP interval.&#xD;
&#xD;
                    -  Mobitz II AV block is characterized by sudden unexpected blocked P waves&#xD;
                       without variation or prolongation of the PR interval. It can be 2:1, 3:1,&#xD;
                       4:1 etc.&#xD;
&#xD;
                    -  Third-degree atrioventricular block:&#xD;
&#xD;
                    -  P waves and QRS complexes without mutual relationship. P wave rate is&#xD;
                       greater than that of QRS complexes.&#xD;
&#xD;
                    -  Ischemia, injury and infarction:&#xD;
&#xD;
                    -  Subendocardial ischemia. - Symmetrical T waves of increased amplitude.&#xD;
&#xD;
                    -  Subepicardial ischemia. - Inverted symmetrical T waves.&#xD;
&#xD;
                    -  Subendocardial injury. - ST segment depression (horizontal or descending).&#xD;
&#xD;
                    -  Subepicardial injury. - ST segment elevation with upper convexity.&#xD;
&#xD;
                    -  Infarction or necrosis. - Q wave voltage greater than 25% of R wave voltage.&#xD;
&#xD;
                    -  Duration of Q wave is 0.04 sec or more&#xD;
&#xD;
               -  History of significant neurological or psychiatric disorders.&#xD;
&#xD;
               -  Active infection; infection by HIV, HBV or HCV. HIV, HBV or HCV testing are not&#xD;
                  required unless infection is clinically suspected.&#xD;
&#xD;
               -  Myopathy or any clinical situation that causes significant and persistent&#xD;
                  elevation of CK (&gt; 2.5 ULN in two different determinations performed with one&#xD;
                  week apart).&#xD;
&#xD;
               -  Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic&#xD;
                  hepatitis).&#xD;
&#xD;
               -  Limitation of the patient's ability to comply with the treatment or follow-up&#xD;
                  protocol.&#xD;
&#xD;
               -  Uncontrolled endocrine diseases (e.g. diabetes mellitus, hypothyroidism or&#xD;
                  hyperthyroidism) (i.e. requiring relevant changes in medication within the last&#xD;
                  month, or hospital admission within the last 3 months).&#xD;
&#xD;
         11. Known hypersensitivity to Aplidin®, mannitol, cremophor EL, or ethanol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Celestia Higano, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Cancer Care Alliance</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maha Hussain, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 27, 2008</study_first_submitted>
  <study_first_submitted_qc>October 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2008</study_first_posted>
  <results_first_submitted>October 11, 2018</results_first_submitted>
  <results_first_submitted_qc>November 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 24, 2020</results_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aplidin</keyword>
  <keyword>Plitidepsin</keyword>
  <keyword>Prostate</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aplidin®</title>
          <description>Aplidin (Plitidepsin)&#xD;
Aplidin (plitidepsin): Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aplidin®</title>
          <description>Aplidin (Plitidepsin)&#xD;
Aplidin (plitidepsin): Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" lower_limit="55.0" upper_limit="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Patients With a ≥ 50% Prostate-specific Antigen (PSA) Decline Post-therapy</title>
        <time_frame>All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aplidin®</title>
            <description>Aplidin (Plitidepsin)&#xD;
Aplidin (plitidepsin): Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients With a ≥ 50% Prostate-specific Antigen (PSA) Decline Post-therapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>PSA Progression</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PSA Stabilization</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PSA Progression NC</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PSA Response NC</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Tumor Response According to RECIST</title>
        <description>Patients with an objective tumor response (complete response [CR] or partial response [PR]) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST), See Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000; 92:205-16.</description>
        <time_frame>All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aplidin®</title>
            <description>Aplidin (Plitidepsin)&#xD;
Aplidin (plitidepsin): Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response According to RECIST</title>
          <description>Patients with an objective tumor response (complete response [CR] or partial response [PR]) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST), See Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000; 92:205-16.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>stable disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>no response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>non evaluable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after 2 previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy.&#xD;
PFS defined as time from the first day of study treatment to the day of a negative outcome (progression according to RECIST (Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000; 92:205-16) or death) or last contact. If any patient is lost to follow up before disease progression, the PFS will be censored at the date of the last tumor assessment. If there are no tumor assessments the patient will be censored at the first drug administration date.</description>
        <time_frame>All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aplidin®</title>
            <description>Aplidin (Plitidepsin)&#xD;
Aplidin (plitidepsin): Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after 2 previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy.&#xD;
PFS defined as time from the first day of study treatment to the day of a negative outcome (progression according to RECIST (Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000; 92:205-16) or death) or last contact. If any patient is lost to follow up before disease progression, the PFS will be censored at the date of the last tumor assessment. If there are no tumor assessments the patient will be censored at the first drug administration date.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" lower_limit="1.4" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after two previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy.&#xD;
Survival is measured from the first day of study treatment to death or day of their last follow-up</description>
        <time_frame>All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aplidin®</title>
            <description>Aplidin (Plitidepsin)&#xD;
Aplidin (plitidepsin): Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after two previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy.&#xD;
Survival is measured from the first day of study treatment to death or day of their last follow-up</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="5.7" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Improvement Rate</title>
        <description>To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after two previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy.&#xD;
Expressed as a change in pain intensity according to the pain intensity score on the 100 mm VAS (Visual Analogue Scale) and/or change in analgesic (morphine-equivalent mg) requirements after a pain stabilization period of 2-7 days&#xD;
Visual Analogue Scale (VAS), expressed in the pain intensity score on the 100 mm VAS scale (0=least possible pain to 100=worst possible pain)</description>
        <time_frame>2-7 days for the pain stabilization required at baseline to ensure that baseline values are stable and reliable. The follow-up period was up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aplidin®</title>
            <description>Aplidin (Plitidepsin)&#xD;
Aplidin (plitidepsin): Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Improvement Rate</title>
          <description>To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after two previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy.&#xD;
Expressed as a change in pain intensity according to the pain intensity score on the 100 mm VAS (Visual Analogue Scale) and/or change in analgesic (morphine-equivalent mg) requirements after a pain stabilization period of 2-7 days&#xD;
Visual Analogue Scale (VAS), expressed in the pain intensity score on the 100 mm VAS scale (0=least possible pain to 100=worst possible pain)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-81.8" upper_limit="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PSA Slope Between Baseline PSA Value and Nadir After the Start of Treatment</title>
        <description>To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after two previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy.&#xD;
It was calculated as (nadir value-baseline value)/(nadir date-baseline date). Modifications in the slope of PSA changes before and after the start of treatment with Aplidin will also be explored.</description>
        <time_frame>From baseline until progression or initiation of another anticancer therapy, death or one year after the last treatment visit of the last patient, whichever occurred first.</time_frame>
        <population>One patient less because there were not PSA measurements after baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Aplidin®</title>
            <description>Aplidin (Plitidepsin)&#xD;
Aplidin (plitidepsin): Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PSA Slope Between Baseline PSA Value and Nadir After the Start of Treatment</title>
          <description>To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after two previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy.&#xD;
It was calculated as (nadir value-baseline value)/(nadir date-baseline date). Modifications in the slope of PSA changes before and after the start of treatment with Aplidin will also be explored.</description>
          <population>One patient less because there were not PSA measurements after baseline</population>
          <units>ng/ml/days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="-1.9" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aplidin®</title>
          <description>Aplidin (Plitidepsin)&#xD;
Aplidin (plitidepsin): Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST-T change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood creatinine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood glucose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Haemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Claustrophobia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Department of PharmaMar´s Oncology,Business Unit.,</name_or_title>
      <organization>Pharma Mar, S.A.</organization>
      <phone>+34 918466000</phone>
      <email>clinicaltrials@pharmamar.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

